Browse > Article
http://dx.doi.org/10.5483/BMBRep.2019.52.9.186

LRRK2 and membrane trafficking: nexus of Parkinson's disease  

Hur, Eun-Mi (Department of Neuroscience, College of Veterinary Medicine, Research Institute for Veterinary Science, and BK21 PLUS Program for Creative Veterinary Science Research, Seoul National University)
Jang, Eun-Hae (Department of Neuroscience, College of Veterinary Medicine, Research Institute for Veterinary Science, and BK21 PLUS Program for Creative Veterinary Science Research, Seoul National University)
Jeong, Ga Ram (Department of Neuroscience, Kyung Hee University)
Lee, Byoung Dae (Department of Neuroscience, Kyung Hee University)
Publication Information
BMB Reports / v.52, no.9, 2019 , pp. 533-539 More about this Journal
Abstract
Recent evidence from genetics, animal model systems and biochemical studies suggests that defects in membrane trafficking play an important part in the pathophysiology of Parkinson's disease (PD). Mutations in leucine-rich repeat kinase 2 (LRRK2) constitute the most frequent genetic cause of both familial and sporadic PD, and LRRK2 has been suggested as a druggable target for PD. Although the precise physiological function of LRRK2 remains largely unknown, mounting evidence suggests that LRRK2 controls membrane trafficking by interacting with key regulators of the endosomal-lysosomal pathway and synaptic recycling. In this review, we discuss the genetic, biochemical and functional links between LRRK2 and membrane trafficking. Understanding the mechanism by which LRRK2 influences such processes may contribute to the development of disease-modifying therapies for PD.
Keywords
LRRK2; Parkinson's disease; Rab; Synaptic vesicle; Vesicle trafficking;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cookson MR (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 11, 791-797   DOI
2 Paisan-Ruiz C, Lewis PA and Singleton AB (2013) LRRK2: cause, risk, and mechanism. J Parkinsons Dis 3, 85-103   DOI
3 Wang X, Yan MH, Fujioka H et al (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21, 1931-1944   DOI
4 Orenstein SJ, Kuo SH, Tasset I et al (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci 16, 394-406   DOI
5 Parisiadou L, Xie C, Cho HJ et al (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29, 13971-13980   DOI
6 Martin I, Kim JW, Lee BD et al (2014) Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell 157, 472-485   DOI
7 Trinh J, Guella I and Farrer MJ (2014) Disease penetrance of late-onset parkinsonism: a meta-analysis. JAMA Neurol 71, 1535-1539   DOI
8 West AB, Moore DJ, Biskup S et al (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102, 16842-16847   DOI
9 Greggio E, Jain S, Kingsbury A et al (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329-341   DOI
10 Lee BD, Shin JH, VanKampen J et al (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16, 998-1000   DOI
11 Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM and Ross CA (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9, 1231-1233   DOI
12 Shin N, Jeong H, Kwon J et al (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314, 2055-2065   DOI
13 West AB, Moore DJ, Choi C et al (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16, 223-232   DOI
14 Lee BD, Dawson VL and Dawson TM (2012) Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends Pharmacol Sci 33, 365-373   DOI
15 Biskup S, Moore DJ, Celsi F et al (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60, 557-569   DOI
16 Piccoli G, Condliffe SB, Bauer M et al (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 31, 2225-2237   DOI
17 Alegre-Abarrategui J, Christian H, Lufino MM et al (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18, 4022-4034   DOI
18 Manzoni C, Denny P, Lovering RC and Lewis PA (2015) Computational analysis of the LRRK2 interactome. PeerJ 3, e778   DOI
19 Tong Y, Yamaguchi H, Giaime E et al (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107, 9879-9884   DOI
20 Dodson MW, Zhang T, Jiang C, Chen S and Guo M (2012) Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum Mol Genet 21, 1350-1363   DOI
21 Stenmark H (2009) Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10, 513-525   DOI
22 Paisan-Ruiz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600   DOI
23 Abeliovich A and Gitler AD (2016) Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature 539, 207-216   DOI
24 Moss J and Bolam JP (2008) A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals. J Neurosci 28, 11221-11230   DOI
25 Matsuda W, Furuta T, Nakamura KC et al (2009) Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci 29, 444-453   DOI
26 Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607   DOI
27 Funayama M, Hasegawa K, Ohta E et al (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57, 918-921   DOI
28 Nalls MA, Pankratz N, Lill CM et al (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46, 989-993   DOI
29 Lesage S, Ibanez P, Lohmann E et al (2005) G2019S LRRK2 mutation in french and north african families with Parkinson's disease. Ann Neurol 58, 784-787   DOI
30 Benamer HT and de Silva R (2010) LRRK2 G2019S in the North African population: a review. Eur Neurol 63, 321-325   DOI
31 Hutagalung AH and Novick PJ (2011) Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev 91, 119-149   DOI
32 Beilina A, Rudenko IN, Kaganovich A et al (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A 111, 2626-2631   DOI
33 Rivero-Rios P, Gomez-Suaga P, Fernandez B et al (2015) Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson's disease. Biochem Soc Trans 43, 390-395   DOI
34 MacLeod DA, Rhinn H, Kuwahara T et al (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77, 425-439   DOI
35 Waschbusch D, Michels H, Strassheim S et al (2014) LRRK2 transport is regulated by its novel interacting partner Rab32. PLoS One 9, e111632   DOI
36 Gomez-Suaga P, Rivero-Rios P, Fdez E et al (2014) LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Hum Mol Genet 23, 6779-6796   DOI
37 Heo HY, Kim KS and Seol W (2010) Coordinate regulation of neurite outgrowth by LRRK2 and Its interactor, Rab5. Exp Neurobiol 19, 97-105   DOI
38 Jeong GR, Jang EH, Bae JR et al (2018) Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Mol Neurodegener 13, 8   DOI
39 Steger M, Tonelli F, Ito G et al (2016) Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, 12813   DOI
40 Liu Z, Bryant N, Kumaran R et al (2018) LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Hum Mol Genet 27, 385-395   DOI
41 Purlyte E, Dhekne HS, Sarhan AR et al (2018) Rab29 activation of the Parkinson's disease-associated LRRK2 kinase. EMBO J 37, 1-18   DOI
42 Steger M, Diez F, Dhekne HS et al (2017) Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. Elife 6, 31012   DOI
43 Simon-Sanchez J, Schulte C, Bras JM et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41, 1308-1312   DOI
44 Pihlstrom L, Rengmark A, Bjornara KA et al (2015) Fine mapping and resequencing of the PARK16 locus in Parkinson's disease. J Hum Genet 60, 357-362   DOI
45 Eguchi T, Kuwahara T, Sakurai M et al (2018) LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis. Proc Natl Acad Sci U S A 115, E9115-E9124   DOI
46 Mazzulli JR, Zunke F, Isacson O, Studer L and Krainc D (2016) alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A 113, 1931-1936   DOI
47 Cooper AA, Gitler AD, Cashikar A et al (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324-328   DOI
48 Gitler AD, Bevis BJ, Shorter J et al (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A 105, 145-150   DOI
49 Dalfo E, Gomez-Isla T, Rosa JL et al (2004) Abnormal alpha-synuclein interactions with Rab proteins in alpha-synuclein A30P transgenic mice. J Neuropathol Exp Neurol 63, 302-313   DOI
50 Saheki Y and De Camilli P (2012) Synaptic vesicle endocytosis. Cold Spring Harb Perspect Biol 4, a005645   DOI
51 Matta S, Van Kolen K, da Cunha R et al (2012) LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 75, 1008-1021   DOI
52 Gallop JL, Jao CC, Kent HM et al (2006) Mechanism of endophilin N-BAR domain-mediated membrane curvature. EMBO J 25, 2898-2910   DOI
53 Masuda M, Takeda S, Sone M et al (2006) Endophilin BAR domain drives membrane curvature by two newly identified structure-based mechanisms. EMBO J 25, 2889-2897   DOI
54 Bai J, Hu Z, Dittman JS, Pym EC and Kaplan JM (2010) Endophilin functions as a membrane-bending molecule and is delivered to endocytic zones by exocytosis. Cell 143, 430-441   DOI
55 Milosevic I, Giovedi S, Lou X et al (2011) Recruitment of endophilin to clathrin-coated pit necks is required for efficient vesicle uncoating after fission. Neuron 72, 587-601   DOI
56 Ambroso MR, Hegde BG and Langen R (2014) Endophilin A1 induces different membrane shapes using a conformational switch that is regulated by phosphorylation. Proc Natl Acad Sci U S A 111, 6982-6987   DOI
57 Hill E, van Der Kaay J, Downes CP and Smythe E (2001) The role of dynamin and its binding partners in coated pit invagination and scission. J Cell Biol 152, 309-323   DOI
58 Verstreken P, Koh TW, Schulze KL et al (2003) Synaptojanin is recruited by endophilin to promote synaptic vesicle uncoating. Neuron 40, 733-748   DOI
59 Islam MS, Nolte H, Jacob W et al (2016) Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease. Hum Mol Genet 25, 5365-5382
60 Edvardson S, Cinnamon Y, Ta-Shma A et al (2012) A deleterious mutation in DNAJC6 encoding the neuronalspecific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One 7, e36458   DOI
61 Koroglu C, Baysal L, Cetinkaya M, Karasoy H and Tolun A (2013) DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord 19, 320-324   DOI
62 Nguyen M and Krainc D (2018) LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease. Proc Natl Acad Sci U S A 115, 5576-5581   DOI
63 Belluzzi E, Gonnelli A, Cirnaru MD et al (2016) LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. Mol Neurodegener 11, 1   DOI
64 Ryu JK, Jahn R and Yoon TY (2016) Review: Progresses in understanding N-ethylmaleimide sensitive factor (NSF) mediated disassembly of SNARE complexes. Biopolymers 105, 518-531   DOI
65 Yu RC, Hanson PI, Jahn R and Brunger AT (1998) Structure of the ATP-dependent oligomerization domain of N-ethylmaleimide sensitive factor complexed with ATP. Nat Struct Biol 5, 803-811   DOI
66 Yun HJ, Park J, Ho DH et al (2013) LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25. Exp Mol Med 45, e36   DOI
67 Tian JH, Wu ZX, Unzicker M et al (2005) The role of Snapin in neurosecretion: snapin knock-out mice exhibit impaired calcium-dependent exocytosis of large dense-core vesicles in chromaffin cells. J Neurosci 25, 10546-10555   DOI
68 Shahmoradian SH, Lewis AJ, Genoud C et al (2019) Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nat Neurosci 22, 1099-1109   DOI